PT  - JOURNAL ARTICLE
AU  - Hitt Nichols, Emma
ED  - Mikhael, Joseph
ED  - Richardson, Paul G.
ED  - Moreau, Philippe
TI  - ASCT for Multiple Myeloma: The Role of the Novel Agents
DP  - 2014  01
TA  - MD Conference Express
PG  - 31--33
VI  - 14
IP  - 55
4099  - http://mdc.sagepub.com/content/14/55/31.short
4100  - http://mdc.sagepub.com/content/14/55/31.full
AB  - With the advent of novel therapies, the mean survival rate of patients with multiple myeloma is now about 10 years. Prior to the approval of the novel therapies, stem cell transplantation was considered the first-line therapy for younger patients with multiple myeloma. Current prospective trials should shed light on delaying stem cell transplantation in favor of first-line treatment, so as to avoid both acute and long term toxicities in the years to come.